Business
Block Listing Application
Block Listing Application.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 0383X Allergy Therapeutics PLC 21 November 2017 \n\n21 November 2017\n \n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nBlock Listing Application\n \n \nAllergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that an application has been made to the London Stock Exchange for admission to AIM for a block listing of 10,000,000 ordinary shares of 0.1p each in the Company (\"Ordinary Shares\").\nThe new Ordinary Shares will not be allotted immediately but rather will be issued and allotted from time to time pursuant to the exercise of employee options under the Allergy Therapeutics 2013 Long Term Incentive Plan. On exercise, these new Ordinary Shares will be issued as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company. \nThe expected effective date of admission of these securities to AIM is on or around 24 November 2017.\n \n- ENDS -\n \n \n \n \n \nFor further information, please contact:\n \nAllergy Therapeutics\n+44 (0) 1903 845 820\nManuel Llobet, Chief Executive Officer\nNick Wykeman, Finance Director\n \nPanmure Gordon\n+44 (0) 20 7886 2500\nFreddy Crossley / Duncan Monteith, Corporate Finance\nTom Salvesen, Corporate Broking\n \nConsilium Strategic Communications\n+44 20 3709 5700\nMary-Jane Elliott / Ivar Milligan / Philippa Gardner\[email protected]\n \nNotes for editors:\n \nAbout Allergy Therapeutics\n \nAllergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.\n \nFormed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in ...